Publications by authors named "W Boehmerle"

Neurologic immune-related adverse events (nirAEs) represent rare, yet severe side effects associated with immune checkpoint inhibitor (ICI) therapy. Given the absence of established diagnostic biomarkers for nirAEs, we aimed to evaluate the diagnostic utility of serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP). Fifty-three patients were included at three comprehensive cancer centers, of these 20 patients with manifest nirAEs and 11 patients with irHypophysitis.

View Article and Find Full Text PDF

Background: Chemotherapy-induced cognitive impairment (CICI) is a well-recognized side effect of breast cancer treatment. However, prospective long-term evaluations of CICI using standardized neuropsychological tests are scarce.

Patients And Methods: This prospective longitudinal cohort study investigated cognitive dysfunction and its impact on quality of life and everyday functioning in patients with breast cancer receiving first-line chemotherapy compared to patients with breast cancer without chemotherapy.

View Article and Find Full Text PDF

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy. The frequency of CIPN ranges from one in three to almost all patients depending on type of chemotherapy and dose. It causes symptoms that can range from sensitivity to touch and numbness to neuropathic pain in hands and feet.

View Article and Find Full Text PDF

Background: Central nervous system (CNS) injury following brain-directed radiotherapy remains a major challenge. Proton radiotherapy (PRT) minimizes radiation to healthy brain, potentially limiting sequelae. We characterized CNS radiotoxicity, including radiation-induced leukoencephalopathy (RIL), brain tissue necrosis (TN), and cerebral microbleeds (CMB), in glioma patients treated with PRT or photons (XRT).

View Article and Find Full Text PDF
Article Synopsis
  • The rise of cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has led to improved survival rates for various cancers, but it also brings significant risks of autoimmunity, including severe neurological side effects.
  • The study focuses on understanding the role of neuronal autoantibodies in ICI-treated patients, exploring their prevalence and potential correlation with adverse neurological effects.
  • This research is the first comprehensive comparison of neuronal autoantibody profiles between ICI-treated cancer patients with and without neurological immune-related adverse events, offering important insights for future clinical and research applications.
View Article and Find Full Text PDF